TIMP-1 (human) AlphaLISA Detection Kit, 100 Assay Points

Formats:

• Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
• Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
• Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

AlphaLISA features:

• No-wash steps, no separation steps
• ELISA alternative technology
• Sensitive detection
• Broad sample compatibility
• Small sample volume
• Results in less than 3 hours
• Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Metalloproteinase Inhibitor 1 / Tissue Inhibitor of Metalloproteinases (TIMPs) are a family of inhibitors binding to most matrix metalloproteinases (MMPs) through their interaction with the Zn²⁺ binding pocket of active MMPs. They are also inhibitors of proteins from the ADAM and ADAMTS families. TIMP-1 is a glycoprotein of 184 amino acids in its active form. High levels of TIMP-1 were observed in many types of cancer, including breast and colon cancer. Increasing the expression of TIMP-1 suppresses the invasiveness of some cancers like melanoma and fibrosarcoma cells. Many studies demonstrated that TIMP-1 can be used as a prognostic marker of survival in patients with breast and colorectal cancer.